There is unlikely to be any pain relief for QRX investors tomorrow as the company heads into what looks to be a challenging session with the FDA's Advisory...

Matthijs Smith

Canaccord Genuity Australia

There is unlikely to be any pain relief for QRX investors tomorrow as the company heads into what looks to be a challenging session with the FDA's Advisory Committee meeting overnight. The briefing documents were posted on the FDA website over the weekend and the Agency make it pretty clear they are non-plussed with QRX's third attempt to get its blessing. QRX's pain drug is somewhat unusual in that it combines two drugs of the same class which has made it more difficult for the Agency to evaluate. However, after running their own analysis, the FDA decided that they could not see any evidence that it worked better. QRX believed their data showed that the combo product had lower rates of respiratory depression but the Agency does not appear to be convinced about this or any other safety benefits. Whatever happens, overnight, it is not going to be pretty.


Matthijs Smith
Senior Life Sciences Analyst
Canaccord Genuity Australia

PhD Human Genetics, MBA, BSc Hons (1st Class). Sell side analyst specialising in life science companies since 2006. Previous background in biotech companies, medical research, consulting with BCG and scientific journalism with Nature

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.